Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortiumLoveleen Bansi‐Matharu, Lene Ryom, Andrew Phillips et al.|The Lancet HIV|2021Cited by 65
Viral Suppression, Viral Failure, and Safety Outcomes in Children and Adolescents With HIV on Dolutegravir in Europe and ThailandKaren Scott, Marc Hainaut, Antoni Noguera‐Julián et al.|Clinical Infectious Diseases|2025Cited by 6
Preferences and willingness for starting daily, on-demand, and long-acting injectable HIV pre-exposure prophylaxis among transfeminine persons in the US, 2022–2023Duygu İşlek, Vani Vannappagari, Travis Sanchez et al.|PLoS ONE|2025Cited by 3
Mortality using raltegravir versus other integrase strand-transfer inhibitors in people with HIV in Europe and Australia: a prospective multicentre studyErich Tusch, Joanne Reekie, Lene Ryom et al.|EClinicalMedicine|2025Cited by 1
Characteristics Associated With the HIV Preexposure Prophylaxis Care Continuum Among Transfeminine Persons in the United StatesDuygu İşlek, Vani Vannappagari, Travis Sanchez et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2025Cited by 0